Severe Atopic Dermatitis

In this video, Raj Chovatiya, MD, PhD, discussed research into the OX40 inhibitor amlitelimab, as well as two topical medications, from the Maui Derm 2024 meeting, examining data into their use in treating atopic dermatitis.

An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.

Pediatric patients with severe atopic dermatitis experienced higher rates of itch, pain, sleep disturbances and missed school days compared with those with mild disease, according to a study.

Long-term trial results showed efficacy of rademikibart in Chinese patients with moderate to severe atopic dermatitis, Connect Biopharma announced in a press release.

The European Commission has approved Ebglyss in the European Union for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, Almirall announced in a press release.

Maintenance dosing of lebrikizumab sustained skin clearance, relieved itch and reduced disease severity for up to 2 years in patients with moderate to severe atopic dermatitis, Eli Lilly and Company announced in a press release.

Amlitelimab exhibited clinically meaningful efficacy over 24 weeks in the treatment of adults with moderate to severe atopic dermatitis, according to study results presented at the European Academy of Dermatology and Venereology 2023 Congress.

Tralokinumab at doses of 150 mg or 300 mg was associated with improvements over placebo in a number of efficacy outcomes at 16 weeks and 52 weeks in adolescents with moderate to severe atopic dermatitis, according to a study.

A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study.

The European Commission approved Dupixent in the European Union for the treatment of severe atopic dermatitis in infants and young children who are candidates for systemic therapy, Sanofi and Regeneron announced in a press release.